登录 | 注册    关注公众号  
微信公众号
搜索
 > 【EGFRvIII】

EGFRvIII信息

英文名称:Epidermal growth factor receptor variant III
中文名称:表皮生长因子受体变体III
靶点别称
上市药物数量:0
临床药物数量:13
最高研发阶段:临床二期

EGFRvIII产品列表

ACRO质量管理体系
 
评论(3)
EGI-HP2E3|PE-Labeled Human EGFRvIII Protein, His Tag (Site-specific conjugation)
  1. 151XXXXXXX5
  2. 1人赞
  3. 购买蛋白是为了做biacore实验,实验发现蛋白的亲和力很好,做出来的结果也很符合理论,实验非常成功,蛋白非常好?
  4. 2021-12-06
EGI-H52H4|Human EGFRvIII Protein, His Tag (MALS verified)
  1. 177XXXXXXX7
  2. 0人赞
  3. 本次购买蛋白为 Human-EGFRvIII蛋白,用于foertebio octet 亲和力实验,实验结果loading信号好,结合也很好。
  4. >
  5. 2022-08-01
EGI-H52H4|Human EGFRvIII Protein, His Tag (MALS verified)
  1. 166XXXXXXX7
  2. 0人赞
  3. 人源EGFRvIII抗原与抗体亲和力很强
  4. >
  5. 2022-10-17
 

EGFRvIII分子别名

EGFRvIII

EGFRvIII分子背景

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point

EGFRvIII临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR 临床二期 美国国立癌症研究所, Kite Pharma 胶质母细胞瘤, 脑癌, 神经胶质肉瘤, 胶质瘤 详情
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 临床二期 三生国健药业(上海)股份有限公司 结直肠癌 详情
WSD-0922 WSD-0922; WSD0922 临床一期 威尚(上海)生物医药有限公司 胶质母细胞瘤, 肿瘤, 星形细胞瘤, 非小细胞肺癌 详情
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 临床一期 宾夕法尼亚大学, 诺华制药 胶质母细胞瘤 详情
EGFRvIII-CAR 临床一期 杜克大学医学中心 胶质母细胞瘤 详情
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) 临床一期 California Institute For Regenerative Medicine, 美国国立癌症研究所 胶质母细胞瘤 详情
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) DCTY0801; DCTY-0801 临床一期 北京鼎成肽源生物技术有限公司 胶质母细胞瘤 详情
SNC-109 SNC109; SNC-109 临床一期 上海先博生物科技有限公司 胶质母细胞瘤 详情
RO-7428731 RO-7428731; RG-6156 临床一期 罗氏 胶质母细胞瘤 详情
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) 临床一期 Chembrain Ltd 胶质母细胞瘤, 胶质瘤 详情
hEGFRvIII-CD3 Bi-scFv 临床一期 杜克大学 胶质母细胞瘤, 胶质瘤 详情
GNC-039 GNC-039 临床一期 四川百利药业有限责任公司 实体瘤, 血液肿瘤, 胶质瘤, 转移癌 详情
Etevritamab AMG-596 临床一期 安进 胶质母细胞瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定